skip to Main Content

Novel FrostBite Cryoablation Technology for the Treatment of Pancreatic Cancer Wins NIH SBIR Phase II Award

Newsfeed image, light gray text on dark gray background
CPSI Biotech (CPSI) announced today it has been awarded a Phase II Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH). The 2 year $1.7 million Phase II project focuses on the development of a next generation cryoablation device (FrostBite ) and approach for the treatment of pancreatic cancer.

Dr. John Baust (CPSI President) commented, “The overall objective of FrostBite is to provide a powerful ablative tool to attack pancreatic cancer, which ultimately may reduce our reliance on other more traditional approaches such as chemotherapy, radiation or major surgery to treat this deadly disease.” The potential impact of the technology is tremendous. Speaking about the technology, Dr. P. Jay Pasricha (Professor of Medicine and Neurosciences, Division of Gastroenterology, John Hopkins School of Medicine and consultant for CPSI) commented “We are very encouraged by the potential of FrostBite EUS-cryocatheter platform. The ability to target and freeze tissues in situ under endoscopic ultrasound guidance will provide for a more precise and minimally invasive strategy to treat cancer including pancreatic, esophageal and other tumors. We are looking forward to continuing our work with CPSI to bring this technology to the clinic.” Read more . . .


Back To Top